Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria

Ifeoma N. Anagbogu1, Yisa A. Saka2, Olabanji Ahmed Surakat3*, Chukwu Okoronkwo2, Emmanuel Davies2, Philip Oyale2, Uwem Friday Ekpo4, Uche V. Amazigo5, Kira Barbre6, Micheal Igbe2, Audrey Nyior2, Solomon M Jacob2, Uduak Gideon Nteun2 and Zaiyanatu Abubakar Umar2

Abstract

Background: Integrated transmission assessment surveys (iTAS) have been recommended for evaluation of the transmission of both lymphatic filariasis (LF) and onchocerciasis as the prevalence of both diseases moves toward their respective elimination targets in Nigeria. Therefore, we conducted an iTAS between May and December 2017 in five local government areas (LGAs), also known as implementation units (IUs), in states of Cross River, Taraba and Yobe in Nigeria.

Methods: The TAS comprised two phases: the Pre-iTAS and the iTAS itself. Three states (Cross River, Taraba and Yobe), comprising five LGAs and 20 communities that have completed five rounds of combined treatment with ivermectin and albendazole for LF and 12 total rounds of ivermectin, were selected for inclusion in the study. All participants were tested with the Filariasis Test Strip (FTS; Alere Inc.) and the Biplex rapid Diagnostic Test (RDT; identifying filaria antigens Ov16/Wb123; Abbott diagnostics Korea Inc.). Pre iTAS included 100 children ages 5-9 in each 4 communities and 300 individuals ages 10 and older in a subset of two communities. For the iTAS, only LGAs where antigenemia prevalence in all sampled communities during the Pre-iTAS was < 2% for LF were selected.

Results: Of the five LGAs included in the study, four met the cutoff of the Pre-iTAS and were included in the iTAS; the Ikom LGA was excluded from the iTAS due to antigenemia prevalence. A total of 11,531 school-aged children from 148 schools were tested for LF and onchocerciasis across these four LGAs, including 2873 children in Bade, 2622 children in Bekwara, 3026 children in Gashaka and 3010 children in Karim Lamido. Using the FTS, all samples from Bade and Karim Lamido were negative, whereas 0.2% of the samples from Bekwara and Gashaka were positive. Using the Biplex RDT, LF prevalence in Bade, Bekwara, Gashaka and Karim Lamido was < 0.1%, 0.5%, 0.4% and < 0.1%, respectively. Moreover, all samples from Bade and Karim Lamido were negative for onchocerciasis, whereas 3.1% and 1.8% of the samples from Bekwara and Gashaka were positive, respectively.

Conclusion: This study has provided additional information on the current burden of onchocerciasis and LF in the four IUs sampled where mass drug administration (MDA) for both infections has been ongoing for years. The study identifies that LF-MDA can be safely stopped in all four of the IUs studied, but that MDA for onchocerciasis needs to...
Africa are estimated to be at risk of infection with onchocerciasis, and at least 169 million people in 31 countries are projected to be at risk at least once a year for about 15 years or more, it is possible to interrupt the transmission of onchocerciasis [4]. Therefore, it may be possible to integrate a therapeutic coverage of 65%, MDA can interrupt the transmission of *W. bancrofti* in a population. Onchocerciasis control and elimination efforts focus on MDA using ivermectin, with sporadic vector control where conditions are favourable [5, 6]. When treatment occurs at least once a year for about 15 years or more, it is possible to interrupt transmission [7].

A total of 583 local government areas (LGAs) are endemic for LF in Nigeria; of these, 567 (97%) have conducted at least one MDA round, with 30 of these 567 LGAs also under post-MDA surveillance. Sixteen LGAs have yet to start MDA due to funding challenges [5]. About 50 million persons in over 40,000 communities in Nigeria are at risk of onchocerciasis infection, accounting for about 40% of the global population at risk. A total of 480 LGAs are targeted for the elimination of onchocerciasis transmission with > 85% geographic coverage currently being achieved [8].

The African Programme for Onchocerciasis Control (APOC), which replaced the Onchocerciasis Control Programme (OCP), supported the control of onchocerciasis through annual or 6-monthly ivermectin-based MDA as well as vector control in selected foci [9]. APOC goals transitioned from the control to the elimination of onchocerciasis after a study that was conducted in Mali and Senegal was published in 2009, which provided the first evidence that the elimination of onchocerciasis was feasible in Africa with ivermectin distribution alone [10]; APOC then developed a framework to guide countries towards elimination [2]. By 2012, the transition from morbidity control to elimination of the transmission of onchocerciasis infection was officially documented in the WHO road map on neglected tropical diseases [11]. In 2016, WHO published guidelines on the criteria for stopping MDA in areas that have completed at least 12–15 years of treatment at a minimum of 80% coverage [4]. One of the conditions for stopping MDA is antibody prevalence of < 0.1% in children aged < 10 years.

National LF programmes focus on a series of critical steps following standardized WHO protocols: (i) mapping to determine endemicity; (ii) implementation of MDA with a minimum of 65% treatment coverage once yearly for at least 5 years in endemic areas; (iii) a survey to determine whether prevalence is low enough for MDA to stop; (iv) post-MDA surveillance; and (v) validation of elimination of LF as a public health problem.

There is substantial overlap between LF and onchocerciasis in Nigeria, with both diseases overlapping in 366 LGAs. In those co-endemic LGAs, ivermectin is distributed with albendazole during MDA campaigns. Filariasis programmes in countries have typically functioned vertically and, until a few years ago, in Nigeria, the decision to start MDA was often made for each disease independently without any consideration of the endemicity of other disease.

As Nigeria begins to reach a sufficient number of effective rounds of MDA for both LF and onchocerciasis, a decision needs to be made on whether an implementation unit (IU) or an evaluation unit (EU) can safely stop MDA for one infection without compromising the success of both elimination programmes. The addition of antibody testing for onchocerciasis into the LF transmission assessment survey (TAS), therefore, could be a cost-effective tool to determine whether additional rounds of MDA with ivermectin might be needed. If the results indicate the presence of ongoing transmission of either LF or onchocerciasis among young children, this will provide sufficient evidence to continue ivermectin MDA. If the results do not indicate ongoing transmission of either infection, however, further investigations, including entomological assessments, will be needed to determine whether it is safe to stop ivermectin MDA for onchocerciasis [4]. Therefore, it may be possible to integrate a

**Background**

Lymphatic filariasis (LF) and onchocerciasis are infections caused by the microscopic nematodes *Wuchereria bancrofti* and *Onchocerca volvulus* transmitted respectively by mosquitoes and black flies of the genus *Simulium* [1, 2]. LF has been found to be endemic in 73 countries, with 1.1 billion individuals projected to be at risk, and at least 169 million people in 31 countries in Africa are estimated to be at risk of infection with onchocerciasis and to require mass drug administration (MDA) [3].

The control strategy for LF in Africa is MDA of single-dose combination therapy with albendazole and ivermectin or diethylcarbamazine [4]. When given for an estimated period of 5–6 years with an annual minimum therapeutic coverage of 65%, MDA can interrupt the transmission of *W. bancrofti* in a population. Onchocerciasis control and elimination efforts focus on MDA using ivermectin, with sporadic vector control where conditions are favourable [5, 6]. When treatment occurs at least once a year for about 15 years or more, it is possible to interrupt transmission [7].

A total of 583 local government areas (LGAs) are endemic for LF in Nigeria; of these, 567 (97%) have conducted at least one MDA round, with 30 of these 567 LGAs also under post-MDA surveillance. Sixteen LGAs have yet to start MDA due to funding challenges [5]. About 50 million persons in over 40,000 communities in Nigeria are at risk of onchocerciasis infection, accounting for about 40% of the global population at risk. A total of 480 LGAs are targeted for the elimination of onchocerciasis transmission with > 85% geographic coverage currently being achieved [8].

The African Programme for Onchocerciasis Control (APOC), which replaced the Onchocerciasis Control Programme (OCP), supported the control of onchocerciasis through annual or 6-monthly ivermectin-based MDA as well as vector control in selected foci [9]. APOC goals transitioned from the control to the elimination of onchocerciasis after a study that was conducted in Mali and Senegal was published in 2009, which provided the first evidence that the elimination of onchocerciasis was feasible in Africa with ivermectin distribution alone [10]; APOC then developed a framework to guide countries towards elimination [2]. By 2012, the transition from morbidity control to elimination of the transmission of onchocerciasis infection was officially documented in the WHO road map on neglected tropical diseases [11]. In 2016, WHO published guidelines on the criteria for stopping MDA in areas that have completed at least 12–15 years of treatment at a minimum of 80% coverage [4]. One of the conditions for stopping MDA is antibody prevalence of < 0.1% in children aged < 10 years.

National LF programmes focus on a series of critical steps following standardized WHO protocols: (i) mapping to determine endemicity; (ii) implementation of MDA with a minimum of 65% treatment coverage once yearly for at least 5 years in endemic areas; (iii) a survey to determine whether prevalence is low enough for MDA to stop; (iv) post-MDA surveillance; and (v) validation of elimination of LF as a public health problem.

There is substantial overlap between LF and onchocerciasis in Nigeria, with both diseases overlapping in 366 LGAs. In those co-endemic LGAs, ivermectin is distributed with albendazole during MDA campaigns. Filariasis programmes in countries have typically functioned vertically and, until a few years ago, in Nigeria, the decision to start MDA was often made for each disease independently without any consideration of the endemicity of other disease.

As Nigeria begins to reach a sufficient number of effective rounds of MDA for both LF and onchocerciasis, a decision needs to be made on whether an implementation unit (IU) or an evaluation unit (EU) can safely stop MDA for one infection without compromising the success of both elimination programmes. The addition of antibody testing for onchocerciasis into the LF transmission assessment survey (TAS), therefore, could be a cost-effective tool to determine whether additional rounds of MDA with ivermectin might be needed. If the results indicate the presence of ongoing transmission of either LF or onchocerciasis among young children, this will provide sufficient evidence to continue ivermectin MDA. If the results do not indicate ongoing transmission of either infection, however, further investigations, including entomological assessments, will be needed to determine whether it is safe to stop ivermectin MDA for onchocerciasis [4]. Therefore, it may be possible to integrate a

**Keywords:** Local government areas, Integrated transmission assessment survey, Pre-TAS, Mass drug administration, Onchocerciasis, Lymphatic filariasis, Nigeria
serologic study that meets the serologic component for stopping MDA for onchocerciasis into a routine LF TAS. Based on this background, the aim of this study was to determine the programmatic feasibility of an integrated LF transmission assessment survey (iTAS) and onchocerciasis epidemiological evaluation for simultaneous assessment of both diseases in potentially co-endemic areas that have completed the recommended period of treatment for both diseases.

**Methods**

**Study sites**

Five LGAs (IUs), namely Ikom and Bekwara, Gashaka and Karim-Lamido and Bade, were selected for inclusion in the Pre-iTAS. These LGAs were selected based on their geographic location across different ecological zones and have successfully conducted a minimum of five effective rounds of ivermectin and albendazole combined treatment for LF, as well as >12 effective rounds of ivermectin treatment alone for onchocerciasis. The last MDA prior to the present study for both infections was conducted from August through to November 2016. Bekwara and Ikom are located in Cross River State, in the South-South geo-political zone, within the tropical rain forest; they are characterized by their flat landscape. Gashaka and Karim Lamido are located in Taraba State, in the North-East geo-political zone, and fall largely within the guinea savanna belt, with undulating landscape dotted with a few mountainous features. The vegetation comprises low forest in the southern part and grassland in the northern part. Bade is located in Yobe state, also in the North-East geo-political zone, but in the arid Sudan Savannah belt.

The location of the study LGAs is shown in Fig. 1. Baseline information, including prevalence (nodule for onchocerciasis and antigenemia for LF) is given in Table 1. Coverage in onchocerciasis MDA (2011–2019) has been >70% in all five selected LGAs except for slight dips in 2016 (Fig. 2). Coverage in LF MDA has been >65% except for Bekwerra, which had low treatment in 2011 through 2013. Data quality issues occur regarding the coverage in some years for the various LGAs in both the onchocerciasis and LF MDA campaigns.

**Study design, selection of study sites and sampling strategies**

The study was divided into two phases: the Pre-iTAS and the main iTAS. The initial phase (Pre-iTAS) was conducted in the five LGAs in April 2017, in accordance with WHO criteria for conducting LF TAS [14]. All LGAs that met the cutoff in the pre-iTAS were included in the iTAS, which was conducted from May through June 2017.
In each selected LGA (IU), two sites were selected to meet the criteria of an LF pre-TAS. This included one LF sentinel site with a high baseline prevalence for LF and one onchocerciasis sentinel site based on a high risk of onchocerciasis infection according to the baseline rapid epidemiological mapping of onchocerciasis (REMO) data. The onchocerciasis sentinel site served as a spot-check site for LF. In each of these two sentinel sites per IU, a total of 300 older children and adults of all ages ≥ 10 years were selected by convenience. They were tested for both LF and onchocerciasis using the Filaria Test Strip (FTS; Alere Inc., Waltham, MA, USA) and the SD BIOLINE Oncho/LF IgG4 Biplex Rapid Diagnostic Test (RDT; identifying filarial antigens Ov16/Wb123; Abbott Diagnostics Korea Inc. Giheung-gu, Republic of Korea).

For the onchocerciasis assessment, two additional first-line communities (sites) were selected in each LGA (IU).
in addition to the LF sentinel site and spot-check site as described above (Table 2). Both additional selected communities had a high risk of onchocerciasis infection according to baseline REMO data. Both were first-line communities (with no settlement between them and pre-identified potential breeding sites). Those persons who were not included in the REMO baseline database were within a radius of 50 km of a baseline REMO site. A total of 100 children aged 5–9 years were sampled in each of the four communities through convenience sampling and tested for both LF and onchocerciasis using FTS and Biplex RDT (Ov16/Wb123).

iTAS
The qualification for inclusion in the iTAS was that all the selected sites in an LGA (IU) achieve < 2% antigenemia prevalence for LF. Any LGA with at least one selected community that had an antigenemia prevalence >2% during pre-iTAS would therefore not progress to be included in iTAS. Using systematic random cluster sampling to give an equal chance of selection for each school and eliminate bias, a minimum of 30 schools were selected from each LGA from a sampling frame of all the primary schools in the LGA. In order to fulfill the current stopping MDA threshold for onchocerciasis, sample sizes were powered to be able to detect an upper 95% confidence interval (CI) threshold of 0.1% in children aged 5–9 years. Target grades chosen to represent the majority of pupils aged 5–9 years were grades 1–3 for public schools and grades 1–4 for private schools. From these target grades in the selected schools, pupils were randomly selected and enrolled in the survey. A total of 2500–2700 participants aged 5–9 years were included in each LGA (Table 3).

Diagnostic testing
Participants were tested using SD BIOLINE Oncho/LF IgG4 Biplex RDT (Ov16/Wb123) and the FTS. Dried blood spots were also taken and stored for additional testing. The Biplex RDT detects antibodies against both the *O. volvulus* Ov16 and the *W. bancrofti* Wb123 antigens. The FTS is an antigen test currently recommended by WHO for use as LF test.

Data analysis
Frequencies and 95% CI for LF antigenemia and Wb123 and Ov16 positivity were determined using SPSS version 21 software (SPSS IBM Corp, Armonk, NY, USA). The 95% CI of the prevalence or frequencies was calculated by using a binomial CI exact test calculator.

Results

Pre-iTAS
**Demographic characteristics of study participants during Pre-iTAS**
A total of 5312 participants from 20 communities were enrolled in the study. Of these 5412 participants, 5244 (98%) were tested across the five LGAs (Table 4). Of the 2101 children aged 5–9 years who were tested in four communities in each LGA, 1052 (50%) were male. Of the 3143 individuals aged ≥ 10 years tested in a subset of two communities in each LGA, 1363 (43%) were male.

**LF antigenemia prevalence during Pre-iTAS**
A total of 5191 valid tests was conducted using FTS. Based on the results of the valid tests, an overall antigenemia prevalence of 0.5% was recorded across all the study sites. Among the LGAs, the highest antigenemia prevalence of 1% (10/1026) was recorded in Ikom LGA in Cross River State, followed by Gashaka LGA (7/1152) in Taraba State and Bekwarra LGA (5/1,011) in Cross River State, with 0.6% prevalence recorded in both of the latter LGAs (Table 5). Among the communities surveyed, Agbaragba in Ikom LGA had the highest prevalence (5.9%; 6/101); no positive cases for LF, based on the FTS results, were recorded in Karim Lamido LGA. In total, there were 14 communities across all study areas where zero antigenemia-positive cases for LF using the FTS were recorded.

**LF and onchocerciasis seroprevalence using the SD Bioline Biplex RDT during Pre-iTAS**
Using the Biplex RDT, a total of 31 LF-seropositive cases (<0.1%) among were detected from the valid tests in all the 20 communities visited for all ages. The highest number (19) was recorded in Bekwarra LGA in Cross River State, while Bade LGA in Yobe State had zero LF-seropositive cases. In only two communities were LF-seropositive cases (3 each) recorded in children aged < 10 years: Agbaragba community in Ikom LGA (3.0%) and Gashaka in Taraba State (3.2%). A total of 317 onchocerciasis-seropositive cases (6.0%) were detected from the valid tests using the Biplex RDT in

---

**Table 3** Schools selected for inclusion in iTAS in the local government areas/implementation units

| State      | LGA (IU)     | Total number of selected schools | Number of children planned to be tested |
|------------|--------------|----------------------------------|----------------------------------------|
| Cross River| Bekwarra     | 34                               | 2590                                   |
| Taraba     | Gashaka      | 30                               | 2500                                   |
|            | Karim Lamido | 52                               | 2700                                   |
| Yobe       | Bade         | 30                               | 2700                                   |
all the 20 communities visited for all ages. The highest number (\(n = 142\)) was recorded in Ikom LGA, followed closely by Bekwarra LGA (126), both in Cross River State (Table 5). No LF-seropositive cases were recorded in Bade LGA in Yobe State and Karim Lamido in Taraba State. Onchocerciasis-seropositive cases, detected with the Biplex RDT, were detected in children aged < 10 years in seven communities, with the highest sero-prevalence of 8.2% being recorded in Shibon community in Gashaka LGA, Taraba State.

Figure 3 shows the prevalence of the Ov16 filarial antigen in Bekwerra (Cross River) and Gashaka (Taraba).

 iTAS
The results of the Pre-iTAS in the studied LGAs indicated that most of the communities had an antigenemia prevalence of < 2%. However, the Ikom LGA did not proceed to/was not included in iTAS due to the 5.9% prevalence recorded among children, who are considered serological markers of new infection, in the Agbaragba community.

Demographic characteristics of study participants during iTAS
A total of 148 schools were visited and sampled across four LGAs. Of these, 131 (88.5%) were classified as rural and 17 (11.5%) as urban. All (100%) communities where

Table 4 Distribution of study participants by age and sex

| S/N | State | LGA  | Name of community | No. of children aged 5 to < 10 years sampled | No. of older children and adults aged 10 years sampled | Total no. of children sampled |
|-----|-------|------|-------------------|---------------------------------------------|---------------------------------------------------|-----------------------------|
|     |       |      |                   | Male | Female | Total | Male | Female | Total | Male | Female | Total | Male | Female | Total |
| 1   | Yobe  | Bade | Dagona            | 54   | 46     | 100   | 99   | 211    | 310   | 410   |
| 2   |       | Gafiwa | Gafiwa          | 58   | 58     | 116   | 0    | 0      | 0     | 116   |
| 3   |       | Tagali | Tagali           | 54   | 51     | 105   | 153  | 158    | 311   | 416   |
| 4   |       | Gwio Kur | Gwio Kura    | 47   | 58     | 105   | 0    | 0      | 0     | 105   |
| Subtotal |      |        |                  | 213  | 213    | 426   | 252  | 369    | 621   | 1047  |
| 5   | Cross River | Ikom | Ukpochi          | 47   | 55     | 102   | 0    | 0      | 0     | 102   |
| 6   |       | Agbaragba | Agbaragba   | 63   | 38     | 101   | 0    | 0      | 0     | 101   |
| 7   |       | Etikpe | Etikpe          | 57   | 53     | 110   | 144  | 154    | 298   | 408   |
| 8   |       | Balep | Balep            | 56   | 60     | 116   | 166  | 139    | 305   | 421   |
| Subtotal |      |        |                  | 223  | 206    | 429   | 310  | 293    | 603   | 1032  |
| 9   | Cross River | Bekwara | Nyanya-Ulim    | 49   | 52     | 101   | 0    | 0      | 0     | 101   |
| 10  |       | Atibulum                | 49   | 51     | 100   | 0    | 0      | 0     | 100   |
| 11  |       | Itetka  | Itetka          | 46   | 55     | 101   | 73   | 215    | 288   | 389   |
| 12  |       | Afrike-Okpeche         | 49   | 51     | 100   | 86   | 218    | 304   | 404   |
| Subtotal |      |        |                  | 193  | 209    | 402   | 159  | 433    | 592   | 994   |
| 13  | Taraba | Gashaka | Shinbon         | 29   | 32     | 61    | 0    | 0      | 0     | 61    |
| 14  |       | Gashaka                | 47   | 46     | 93    | 0    | 0      | 0     | 93    |
| 15  |       | Mayo-Selbe             | 115  | 81     | 196   | 249  | 102    | 351   | 547   |
| 16  |       | Nyabar                 | 38   | 32     | 70    | 160  | 221    | 381   | 451   |
| Subtotal |      |        |                  | 229  | 191    | 420   | 409  | 323    | 732   | 1152  |
| 17  | Taraba | K/Lamido | Bandawa         | 53   | 58     | 111   | 103  | 207    | 310   | 421   |
| 18  |       | Panya O                | 51   | 52     | 103   | 130  | 165    | 295   | 398   |
| 19  |       | Gwomu O                | 52   | 52     | 104   | 0    | 0      | 0     | 104   |
| 20  |       | Kodei O                | 38   | 68     | 106   | 0    | 0      | 0     | 106   |
| Subtotal |      |        |                  | 194  | 230    | 424   | 233  | 372    | 605   | 1029  |
| Total |       |        |                  | 1052 | 1049   | 2101  | 1363 | 1780   | 3143  | 5244  |
Table 5  LF prevalence by the Filariasis Test Strip, and seroprevalence of onchocerciasis (Ov16) and LF (Wb123) with the Biplex Rapid Diagnostic Test by age group

| State | LGA     | Community | Village type | Total no. valid FTS tests | No. of positive FTS results in children aged 5 to ≤ 10 years (%) | No. of positive FTS results in older children and adults aged ≥ 10 years (%) | Total no. valid Biplex RDT in children aged 5 to ≤ 10 years (%) | No. positive Biplex RDT in children aged ≥ 10 years (%) | Total no. positive Biplex RDT results (%) |
|-------|---------|-----------|--------------|---------------------------|---------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|--------------------------------------------|
|       | Yobe    | Bade      | Dagona       | 400                       | 0                                                             | 0                                                                           | 410                                                            | 0                                                             | 0                                          |
|       |         |           | Gafiwa FL    | 116                       | 0                                                             | ND                                                                         | 116                                                            | 0                                                             | ND                                         |
|       |         |           | Tagali       | 380                       | 1 (0.3)                                                        | 2 (0.5)                                                                    | 3 (0.8)                                                        | 415                                                            | 0                                          |
|       |         |           | Gwio Kura FL | 105                       | 0                                                             | ND                                                                         | 105                                                            | 0                                                             | ND                                         |
| Subtotal |       |           |              | 1001                      | 1 (0.1)                                                        | 2 (0.2)                                                                    | 3 (0.3)                                                        | 1046                                                          | 0                                          |
|       | Cross R | Ikom      | Ukpochi FL   | 102                       | 0                                                             | ND                                                                         | 102                                                            | 0                                                             | ND                                         |
|       |         |           | Agbaragba FL | 101                       | 6 (5.9)                                                        | ND                                                                         | 6 (5.9)                                                        | 101                                                            | 1 (1.0)                                    |
|       |         |           | Etikpe       | 405                       | 0                                                             | 0                                                                           | 0                                                             | 408                                                            | 2 (0.5)                                    |
|       |         |           | Balep        | 418                       | 0                                                             | 4 (1.0)                                                                    | 4 (1.0)                                                        | 421                                                            | 1 (0.24)                                   |
| Subtotal |       |           |              | 1026                      | 6 (0.6)                                                        | 4 (0.4)                                                                    | 10 (1.0)                                                       | 1032                                                          | 4 (0.4)                                    |
|       | Cross R | Bekwara   | Nyanya-Ulum  | 101                       | 0                                                             | ND                                                                         | 0                                                             | 100                                                            | 4 (4)                                      |
|       |         |           | Atibulum FL  | 100                       | 0                                                             | ND                                                                         | 0                                                             | 100                                                            | 0                                          |
|       |         |           | Itekpa       | 407                       | 2 (0.5)                                                        | 1 (0.0)                                                                    | 6 (1.5)                                                        | 407                                                            | 0                                          |
|       |         |           | Afrike-Okepe  | 403                      | 0                                                             | 0                                                                           | 4 (1.0)                                                        | 404                                                            | 0                                          |
| Subtotal |       |           |              | 1011                      | 2 (0.2)                                                        | 4 (0.4)                                                                    | 6 (0.6)                                                        | 1011                                                          | 4 (0.4)                                    |
|       | Taraba  | Gashaka   | Shinbon FL   | 61                        | 0                                                             | ND                                                                         | 0                                                             | 61                                                             | 5 (8.2)                                    |
|       |         |           | Gashaka FL   | 93                        | 0                                                             | ND                                                                         | 0                                                             | 93                                                             | 3 (3.2)                                    |
|       |         |           | Mayo-Selbe   | 547                       | 1 (2.1)                                                        | 2 (0.4)                                                                    | 3 (0.6)                                                        | 547                                                            | 4 (0.7)                                    |
|       |         |           | Nyabar       | 451                       | 0                                                             | 4 (0.9)                                                                    | 0                                                             | 451                                                            | 3 (0.7)                                    |
| Subtotal |       |           |              | 1152                      | 1 (0.1)                                                        | 6 (0.5)                                                                    | 7 (0.6)                                                        | 1152                                                          | 12 (1.0)                                   |
|       | Taraba  | K/Lamido  | Bandawa      | 395                       | 0                                                             | 0                                                                           | 0                                                             | 421                                                            | 0                                          |
|       |         |           | Panya O      | 396                       | 0                                                             | 0                                                                           | 0                                                             | 396                                                            | 0                                          |
|       |         |           | Gwomu O FL   | 104                       | 0                                                             | ND                                                                         | 0                                                             | 104                                                            | 0                                          |
|       |         |           | Kodei O FL   | 106                       | 0                                                             | ND                                                                         | 0                                                             | 106                                                            | 0                                          |
| Subtotal |       |           |              | 1001                      | 0                                                             | 0                                                                           | 0                                                             | 1029                                                          | 2 (0.2)                                    |

LF lymphatic filariasis, FTS Filariasis Test Strip (FTS; Alere Inc.), LF lymphatic filariasis, ND not determined, Ov16/Wb123 filarial antigens, RDT rapid diagnostic test (SD BIOLINE Oncho/LF IgG4 Biplex RDT [Ov16/Wb123])
these schools were located had conducted 17–21 oncho-
cerciasis MDA rounds and five to seven LF MDA rounds. 
Total enrolment in the sampled schools within the tar-
geted grades were 17,707 children (Table 6). The high-
est number of pupils (11,533) were tested in Gashaka 
LGA. Both genders were equally represented, with 5804 
(50.3%) female pupils and 5729 (49.7%) male pupils.

**LF antigenemia prevalence during iTAS**

Twelve LF antigenemia-positive cases (0.1%) were 
recorded in all the four LGAs included in the iTAS, of 
which six (50%) were in pupils in Grade one, one (8.3%) 
in a pupil in Grade two and five (41.7%) in pupils in Grade 
three. No case was recorded in pupils in Grade four. LF 
antigenemia-positive cases were found in pupils of both 
genders at about the same proportions. Gashaka and 
Bekwerra LGAs had antigenemia prevalence of 0.2% and 
0.2%, respectively, while zero prevalence was observed 
in both Bade and Karim Lamido LGAs. Of the total 12 
positive cases, 11 (91.7%) were in children aged <10 years 
and one (8.3%) was in a child in the ≥10-year age group 
(Table 6).

**LF and onchocerciasis seroprevalence using SD Bioline Biplex RDT during iTAS**

A total of 29 LF-seropositive cases (0.3%) were recorded 
from the valid tests using the Biplex RDT in all of the 148 
schools visited. Of these cases, 12 (41.4%) were in pupils 
in Grade one, seven (24.1%) were in pupils in Grade two, 
and 10 (34.5%) were in pupils in Grade three. No case 
was recorded in pupils in Grade four. The majority (19, 
65.5%) of pupils who tested positive were male. Bekwerra 
and Gashaka LGAs had almost the same seroprevalence: 
0.5% and 0.4%, with 14 and 13 cases, respectively. Both 
Bade and Karim Lamido LGAs had one case each, with 
a seroprevalence of 0.03%. Among the 148 schools sam-
ples, 19 (12.8%) had pupils who tested positive (>0%), 
with the highest site-specific prevalence of 7.9% observed 
in Bekwerra LGA. A total of 135 onchocerciasis-sero-
positive cases (1.2%) were recorded from the valid tests 
using the Biplex RDT in the four sites; of these, 77 (57%) 
were male pupils and 58 (43%) were female pupils. A total 
of 99 (73.3%) seropositive cases were recorded among 
children aged <10 years and 36 (26.7%) among children 
aged ≥10 years. Children in Grade three had the highest 
number of positive cases (53, 39.3%) followed by those
Table 6  Prevalence of LF antigenemia by FTS, LF Wb123 antibody by Biplex RDT and onchocerciasis Ov16 antibody by Biplex RDT, by gender, grade, age group and district

| LGV/INU | No. of pupils tested | Gender | Grade | Age group |
|---------|----------------------|--------|-------|-----------|
|         |                      | Male   | Female| 1   | 2   | 3   | 4   | Age < 5 years | Age 5–9 years | Age 10+ years |
|         |                      | 1387   | 1488  | 1028| 1032| 775 | 40  | 0            | 2388          | 487           |
| Bade    | Number tested        | 2875   | 1387  | 1488| 1028| 1032| 775 | 40  | 0            | 2388          | 487           |
|         | Number FTS positive (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA           | 0 (0)          | 0 (0)         |
|         | Number Biplex-LF positive (%) | 1 (< 1) | 1 (< 1) | 0 (0) | 1 (< 1) | 0 (0) | 0 (0) | 0 (0) | NA           | 1 (< 1)        | 0 (0)         |
|         | Number Biplex-oncho positive (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA           | 0 (0)          | 0 (0)         |
|         |                      | 2622   | 1343  | 1279| 1141| 680 | 721 | 80  | 0            | 2222          | 400           |
|         | Number FTS positive (%) | 5 (< 1) | 3 (< 1) | 2 (< 1) | 3 (< 1) | 0 (0) | 2 (< 1) | 0 (0) | NA           | 5 (< 1)        | 0 (0)         |
|         | Number Biplex-LF positive (%) | 14 (1) | 10 (1) | 4 (< 1) | 6 (1) | 3 (1) | 5 (1) | 0 (0) | NA           | 12 (1)        | 2 (1)         |
|         | Number Biplex-oncho positive (%) | 81 (3) | 35 (2) | 46 (4) | 28 (2) | 26 (4) | 27 (4) | 0 (0) | NA           | 67 (3)        | 14 (3.5)      |
|         |                      | 3026   | 1561  | 1465| 1325| 855 | 846 | 0   | 0            | 2551          | 475           |
|         | Number FTS positive (%) | 7 (< 1) | 4 (< 1) | 3 (< 1) | 3 (< 1) | 1 (< 1) | 3 (< 1) | NA  | NA           | 6 (< 1)        | 1 (< 1)      |
|         | Number Biplex-LF positive (%) | 13 (1) | 8 (1) | 5 (< 1) | 5 (1) | 4 (< 1) | 4 (1) | NA  | NA           | 8 (< 1)        | 5 (1)        |
|         | Number Biplex-oncho positive (%) | 53 (2) | 42 (3) | 11 (1) | 8 (1) | 19 (2) | 26 (3) | NA  | NA           | 31 (1)        | 22 (5)       |
| Gashaka | Number tested        | 3026   | 1561  | 1465| 1325| 855 | 846 | 0   | 0            | 2551          | 475           |
|         | Number FTS positive (%) | 7 (< 1) | 4 (< 1) | 3 (< 1) | 3 (< 1) | 1 (< 1) | 3 (< 1) | NA  | NA           | 6 (< 1)        | 1 (< 1)    |
|         | Number Biplex-LF positive (%) | 13 (1) | 8 (1) | 5 (< 1) | 5 (1) | 4 (< 1) | 4 (1) | NA  | NA           | 8 (< 1)        | 5 (1)       |
|         | Number Biplex-oncho positive (%) | 53 (2) | 42 (3) | 11 (1) | 8 (1) | 19 (2) | 26 (3) | NA  | NA           | 31 (1)        | 22 (5)      |
| Karim Lamido | Number tested | 3010   | 1438  | 1572| 1321| 777 | 912 | 0   | 0            | 2241          | 516           |
|         | Number FTS positive (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA           | 0 (0)          | 0 (0)         |
|         | Number Biplex-LF positive (%) | 1 (< 1) | 0 (0) | 1 (< 1) | 0 (0) | 1 (< 1) | NA  | 0 (0) | 1 (< 1)        | 0 (0)         |
|         | Number Biplex-oncho positive (%) | 1 (< 1) | 0 (0) | 1 (< 1) | 0 (0) | 0 (0) | 0 (0) | NA  | NA           | 0 (0)          | 0 (0)         |

NA Data not available
in Grade two (45, 33.33%) cases, and then children in Grade one (37 cases, 27.4%). No seropositive cases were recorded among children in Grade four. Of the four sites, the highest seroprevalence (3.1%, 81 cases) was recorded in Bekwerra LGA. Bade LGA had zero sero-prevalence. Only one positive case (0.003%) was observed in Karim Lamido LGA while 1.8% seroprevalence (53 cases) was recorded in Gashaka LGA. Sero-prevalence among those children aged < 10 years was 1.1%, with Bekwerra having 3% seroprevalence and Gashaka a seroprevalence 1.2% among this age group. Of the 148 schools sampled, onchocerciasis-positive cases were recorded in 46 (31.1%) schools, with a seroprevalence > 0.1%, with the highest site-specific prevalence of 22.9% recorded in Gashaka LGA. Of these 46 schools, 24 were located in Bekwerra LGA and 20 were located in Gashaka LGA. Five schools (3 in Gashaka LGA and 2 in Bekwerra LGA) had an onchocerciasis seroprevalence > 10% (Table 6).

Discussion
Effective monitoring and evaluation are important components of MDA programmes throughout their life span. They are needed to effectively assess whether the infection being addressed has been reduced to levels at which both transmission may be assumed to be no longer sustainable and recrudescence is unlikely to occur even in the absence of drug intervention [15]. Surveillance should target the entire population in an EU or IU. However, due to limited resources and time constraints, a careful selection of sites and consideration of the most vulnerable population to be monitored are needed. The preliminary results from the pre-iTAS conducted with FTS indicate an overall LF antigenemia prevalence of 0.1% with slight insignificant variations among the IUs. Bade and Karim-Lamido LGAs had zero antigenemia prevalence, while Bekwara and Gashaka LGAs had 0.2%. However, in Gashaka LGA, antigenemia prevalence was above 2%. The findings are consistent with the results obtained from the pre-iTAS (with the exception of those on onchocerciasis seroprevalence from Bekwerra and Gashaka LGAs). Interestingly, the pre-iTAS LF results from Bekwerra LGA, which were close to the 2% sero-prevalence criteria to qualify for the iTAS, improved in the subsequent iTAS, for which 0.2% seroprevalence was recorded, thus justifying the decision to include this LGA in the iTAS. This result may suggest that for LF, pre-iTAS LGAs for which the results are either below or above the 2% antigenemia prevalence cut-off should be considered for inclusion in the iTAS. However, the observed prevalence for each of the two sites evaluated during the pre-iTAS in Bekwerra LGA had a wider margin (i.e. sentinel 4 [1%] vs spot-check 15 [3.7%] when compared with other IUs). This result suggests that the transmission intensity varies between communities within an IU, irrespective of whether the aggregated estimate is 1.9%. It is therefore important that actions taken within a programme are tailored towards disaggregated estimates, as aggregated estimates may mask disease distribution patterns and, hence, mislead programmatic decision-making [16].

Nevertheless, based on the WHO guidelines [4], four LGAs were deemed to have passed TAS for LF. However, in IUs where prevalence exceeds 2%, targeted MDA would be implemented irrespective of the outcomes of this iTAS. Subject to the availability of resources, however, it will be suitable to conduct additional treatment campaigns targeted at the ‘hotspot’ schools and to further conduct tests following the second round of treatment to determine whether transmission is ongoing.

The Wb123/Ov16 Biplex RDT results suggest that transmission of onchocerciasis infection may have been interrupted in Bade and Karim Lamido LGAs, given the zero seroprevalence recorded during the iTAS. This result is further corroborated to a large extent by similar results from the pre-iTAS. Nevertheless, these results are not sufficient to recommend a stop/halt for onchocerciasis MDA in any of these LGAs for two major reasons: (i) type of test use and (ii) the unit of evaluation. Firstly, the biplex serological test used is not yet approved as a tool for surveillance. Similarly, the Ov16 RDT serological test, which has been approved for surveillance, is not to be solely utilized for making decisions in whether or not to stop onchocerciasis MDA. As such, we collected dried blood smears for future laboratory testing with an Ov16 enzyme-linked immunosorbent assay (ELISA) or other test that may be available in the future. Secondly, the decision to stop MDA for onchocerciasis is made at the level of transmission zones, which vary by country, unlike IUs for LF. This has been previously demonstrated in the states of Plateau and Nassarawa in Nigeria. In Nigeria, the National Onchocerciasis Elimination Committee, an advisory body to the government, has decided to use the state as the evaluation unit for the stop-MDA decision, taking into consideration the large expanse of overlapping transmission sites across the IUs. As such, the decision to stop onchocerciasis MDA will require a state-wide assessment followed by entomological evaluation of adult black flies to determine <½000 infectivity rate before pronouncing any stop of the MDA [5, 17].

The current status of LF recorded in the studied LGAs was expected given the treatment coverage of > 85% achieved annually, which had initially qualified these LGAs for inclusion in the Pre-iTAS, the low pre-intervention antigenemia prevalence of <10%, with three of the five LGAs studied having ≤ 2.0% antigenemia prevalence, and the long history of treatment with ivermectin,
ranging between 17 and 21 years. This result agrees with pre-existing notions on the possibility of an indirect or overlapping microfilaricidal effect of ivermectin MDA on LF transmission [18].

The relatively high level of transmission of onchocerciasis observed in Gashaka raises concern. Although the pre-intervention endemicity and outcomes of previous epidemiological assessments using skin snips had been high [19], the impact of mass treatment over the years ought to have been observed in the pattern of endemicity. Similarly, the relatively high transmission of onchocerciasis in Bekwerra LGA was unexpected due to the low pre-intervention endemicity and the long history of annual treatments in this LGA. It is noticeable that transmission remains ongoing in both Bekwerra and Gashaka LGAs based on the level of seroprevalence recorded among children, who are serological markers of a new infection. These may be due to inadequate compliance to (attrition, fatigue) annual treatment by the target populations in those areas. Consequently, strengthening of MDA interventions and the supervision process is of critical importance [16].

The Ov16 results from both the pre-iTAS and iTAS revealed a number of important issues. Results for Ov16 during the iTAS indicated that prevalence increased with age. Given this outcome, a sampling strategy that includes children aged 5–9 years compared to those aged 6–7 years, as in traditional LF TAS, resulted in a more conservative pre-stopping assessment. WHO may therefore reconsider the justification to include children in this age bracket in future assessments. The pre-iTAS results indicated that purposeful selection of first-line villages was insufficient at identifying the sites with the highest Ov16 prevalence by RDT in children aged 5–9 years, suggesting that random sampling may be necessary to identify sites with the potential transmission. However, in employing random sampling there may be a need to exclude from the sampling frame all villages with known information or a high likelihood of being in very low endemic areas based on latest entomological and/or epidemiological assessments. It has been advised that exclusion mapping be done before selection of villages for assessment [20].

**Conclusion**

This study provides additional information on the current burden of onchocerciasis and LF in the four IUs sampled and identified that LF-MDA can be safely stopped in all IUs, although an additional round of MDA in schools where antigenemia prevalence is > 2% is recommended. MDA for onchocerciasis needs to continue, although this may pose a challenge for LF surveillance. Xeno-monitoring of blackflies in LGAs where the threshold for onchocerciasis elimination by serological assessment has been met in the context of the Operational Research OR study sites is recommended, followed by strengthening of onchocerciasis MDA and improved supportive supervision, particularly in Bekwerra and Gashaka LGAs. Based on the preliminary results from all four sites, this study has fulfilled the primary objective of determining the programmatic feasibility of an iTAS to be used to simultaneously assess onchocerciasis and LF prevalence in areas co-endemic for the two infections that have completed the recommended treatment for one or both infections, and to make decisions on how to proceed.

**Acknowledgements**

The authors thank the Director and staff at the NTD Support Center at the Task Force for Global Health for logistic support and technical guidance. Technical facilitation from PATH and the US Centres for Disease Control (CDC) during project implementation are also appreciated. The Mission to Save the Helpless (Mitosath) is appreciated for its exceptional logistic support. The logistic assistance from the country office of the Research Triangle Initiative (RTI) as well as Health and Development Support Programme (HANDS) is valued. We thank the Ministries/Departments of Health, Ministries/Departments of Education and SUBEB office in the participating States and LGAs for their collaboration and policy direction. Finally, our appreciation goes to: the NTD coordinators and programme staff at State and LGA levels for all the preliminary arrangements and project facilitation; Head Teachers and staff of the participating schools for their cooperation; the pupils that registered and were tested; and the drivers and local guides that facilitated movements from one locality to another.

**Author contributions**

OC, SOA, AIN, SYA and DE conceived and initiated the study. OC, SOA, OP, SJ, NG, UZ and IM prepared the tables. BK and EUF prepared the figures. AIN, SYA, SOA, OC, DE, OP, IM, NA, EUF, AUA, BK, SJ, NG and UZ prepared the article. All authors read and approved the final manuscript.

**Funding**

This work received financial support from the Coalition for Operational Research on Neglected Tropical Diseases, which is funded at the Task Force for Global Health primarily by the Bill & Melinda Gates Foundation, by the US Agency for International Development through its Neglected Tropical Diseases Program; and with UK aid from the British people.

**Availability of data and materials**

All data will be made available to the journal.

**Declarations**

**Ethics approval and consent to participate**

Ethical clearance for the study was obtained from the Federal Ministry of Health’s Ethics Committee in the Department of Planning and Research. Details of the procedure were explained to all participants and heads of the schools during social mobilisation. Verbal assent of the Head Teachers as well as informed consent from parents and legal guardian of all children that participated were sought. Participation was voluntary.

**Consent for publication**

All authors consent to the publication of this research work.

**Competing interests**

The authors declare no competing interest.
1. Brattig NW, Cheke RA, Garms R. Onchocerciasis (river blindness)—more than a century of research and control. Acta Trop. 2021;218:105677.
2. Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis elimination: progress and challenges. Res Rep Trop Med. 2020;11:81–95.
3. WHO. African programme for onchocerciasis control: progress report, 2013–2014. Wkly Epidemiol Rec. 2014;89:S51–60.
4. WHO. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: World Health Organization; 2016. Document number: WHO/HTM/NTD/ PCT/2016.4. https://apps.who.int/iris/handle/10665/204180. Accessed 28 June 2020.
5. Federal Ministry of Health (FMoH) Nigeria. Neglected tropical diseases nigeria multi-year master plan 2015–2020. 2016. https://espen.afro.who.int/system/files/content/resources/NIGERIA_NTD_Master_Plan_2015_2020.pdf. Accessed 7 Math, 2020.
6. WHO & African Programme for Onchocerciasis Control. Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. 2010. https://apps.who.int/iris/handle/10665/275466. Accessed 13 Feb 2020.
7. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3:e497.
8. Ojurongbe O, Akindele AA, Adeleke MA, Oyedeji MO, Adebokun SA, Ojo JF, et al. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria. PLoS Negl Trop Dis. 2015;9:e0003633.
9. Amazigo U. The African programme for onchocerciasis control (APOC). Ann Trop Med Parasitol. 2008;102:19–22.
10. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6:e1825.
11. Dolo H, Coulibaly YI, Sov M, Dembélé M, Doumbia SS, Coulibaly SY, et al. Serological evaluation of onchocerciasis and lymphatic filariasis elimination in the Bakoye and Falémé Foci. Mali Clin Infect Dis. 2021;72:1585–93.
12. WHO. Accelerating work to overcome the impact of neglected tropical diseases: a roadmap for implementation. 2012. https://apps.who.int/iris/handle/10665/70809. Accessed 3 Feb 2020.
13. https://www.health.gov.ng/doc/NLFEP_Assessment_Guidelines_August_2019_07012020.pdf. Accessed 3 Feb 2020.
14. WHO. Global programme to eliminate lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration- a manual for national elimination programs. 2011. https://apps.who.int/iris/handle/10665/44580. Accessed 3 Feb 2020.
15. Chu BK, Deming M, Britwum NK, Bougma WR, Dorkenoo AM, et al. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis. 2013;7:e23584.
16. Mogaji HO, Dedeko GA, Bada BS, Bankole S, Adeniji A, Fagbenro MT, et al. Distribution of ascariasis, trichuriasis and hookworm infections in Ogun State, Southwestern Nigeria. PLoS ONE. 2020;15:e0233423.
17. Federal Ministry of Health (FMoH) Nigeria. National onchocerciasis elimination plan. 2017. https://www.cartercenter.org/resources/pdf/news/health_publications/river_blindness/nigeria-onchocerciasis-elimination-plan-feb2017.pdf. Accessed 3 Feb 2020.
18. Cao W, Van der Ploeg CPB, Plaisier AP, Van der Sluis IJ, Lammie PJ. Ivermectin for the chemotherapy of ban-croftian filariasis: a meta-analysis of the effect of single treatment. Trop Med Int Health. 1997;2:393–403.
19. Idowu ET, Adeneye AK, Adeleke MA, Sulyman MA, Mafe MA. Endemicity of onchocerciasis in some communities in Taraba State, Nigeria, following long term treatment with ivermectin. Zoology. 2013;1:21–8.
20. WHO. Report on the fourth meeting of the onchocerciasis technical advisory subgroup: virtual meeting, 28–29 October 2020. 2020. https://www.who.int/publications/i/item/9789240037977. Accessed 3 February 2020.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.